News

Enter your email address to get Core One Labs News Alerts.

News

Enter your email address to get Core One Labs News Alerts.
Company News
September 30, 2022
Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
Vancouver, British Columbia, Canada – September 30, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
September 23, 2022
Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
Vancouver, British Columbia, Canada – September 23, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
September 16, 2022
Core One Labs’ Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
Vancouver, British Columbia, Canada – September 16, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
September 02, 2022
Core One Labs’ Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
Second Ground Breaking Technological Advancement   Vancouver, British Columbia, Canada – September 2, 2022 – Core One Labs Inc. (CSE: COOL),...
Read more
Company News
September 01, 2022
Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
Vancouver, British Columbia, Canada – September 1 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
August 30, 2022
Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction
Vancouver, British Columbia, Canada - August 30, 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (FWB: LD6,...
Read more